1st Global Advisors Inc. Has $382,000 Stake in Novo Nordisk A/S (NVO)

1st Global Advisors Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 38.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,152 shares of the company’s stock after buying an additional 3,107 shares during the period. 1st Global Advisors Inc.’s holdings in Novo Nordisk A/S were worth $382,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp increased its position in Novo Nordisk A/S by 0.4% in the fourth quarter. State Street Corp now owns 8,671 shares of the company’s stock valued at $311,000 after buying an additional 36 shares in the last quarter. Hilltop Holdings Inc. increased its position in Novo Nordisk A/S by 0.9% in the fourth quarter. Hilltop Holdings Inc. now owns 7,814 shares of the company’s stock valued at $280,000 after buying an additional 66 shares in the last quarter. Mycio Wealth Partners LLC increased its position in Novo Nordisk A/S by 0.5% in the third quarter. Mycio Wealth Partners LLC now owns 20,410 shares of the company’s stock valued at $849,000 after buying an additional 97 shares in the last quarter. Pettyjohn Wood & White Inc. increased its position in Novo Nordisk A/S by 0.7% in the third quarter. Pettyjohn Wood & White Inc. now owns 13,525 shares of the company’s stock valued at $563,000 after buying an additional 100 shares in the last quarter. Finally, Legacy Capital Partners Inc. increased its position in Novo Nordisk A/S by 1.4% in the third quarter. Legacy Capital Partners Inc. now owns 7,290 shares of the company’s stock valued at $304,000 after buying an additional 100 shares in the last quarter. 6.38% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Shares of Novo Nordisk A/S (NYSE:NVO) opened at 43.20 on Friday. The firm has a market capitalization of $107.82 billion, a P/E ratio of 18.86 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $57.41. The firm has a 50 day moving average price of $41.60 and a 200-day moving average price of $36.77.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/06/17/1st-global-advisors-inc-acquires-3107-shares-of-novo-nordisk-as-nvo-updated-updated.html.

Several research firms recently commented on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, March 8th. TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday. Barclays PLC initiated coverage on Novo Nordisk A/S in a research note on Tuesday, March 7th. They issued an “underweight” rating for the company. Finally, HSBC Holdings plc downgraded Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $57.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply